Safety evaluation of the single-dose Ad26. COV2.S vaccine among healthcare workers in the Sisonke study in South Africa : a phase 3b implementation trial
JavaScript is disabled for your browser. Some features of this site may not work without it.
| dc.contributor.author | Takuva, Simbarashe G.
|
|
| dc.contributor.author | Takalani, Azwidhwi
|
|
| dc.contributor.author | Seocharan, shen
|
|
| dc.contributor.author | Yende-Zuma, Nonhlanhla
|
|
| dc.contributor.author | Reddy, Tarylee
|
|
| dc.contributor.author | Engelbrecht, Imke
|
|
| dc.contributor.author | Faesen, Mark
|
|
| dc.contributor.author | Khuto, Kentse
|
|
| dc.contributor.author | Whyte, Carmen J.
|
|
| dc.contributor.author | Bailey, Veronique
|
|
| dc.contributor.author | Trivella, Valentina
|
|
| dc.contributor.author | Peter, Jonathan
|
|
| dc.contributor.author | Opie, Jessica
|
|
| dc.contributor.author | Louw, Vernon
|
|
| dc.contributor.author | Rowji, Pradeep
|
|
| dc.contributor.author | Jacobson, Barry
|
|
| dc.contributor.author | Groenewald, Pamela
|
|
| dc.contributor.author | Dorrington, Rob E.
|
|
| dc.contributor.author | Laubscher, Ria
|
|
| dc.contributor.author | Bradshaw, Debbie
|
|
| dc.contributor.author | Moultrie, Harry
|
|
| dc.contributor.author | Fairall, Lara
|
|
| dc.contributor.author | Sanne, Ian
|
|
| dc.contributor.author | GailBekker, Linda
|
|
| dc.contributor.author | Gray, Glenda
|
|
| dc.contributor.author | Goga, Ameena Ebrahim
|
|
| dc.contributor.author | Garrett, Nigel
|
|
| dc.date.accessioned | 2022-11-02T11:55:06Z | |
| dc.date.available | 2022-11-02T11:55:06Z | |
| dc.date.issued | 2022-06-21 | |
| dc.description.abstract | Real-world evaluation of the safety profile of vaccines after licensure is crucial to accurately characterise safety beyond clinical trials, support continued use, and thereby improve public confidence. The Sisonke study aimed to assess the safety and effectiveness of the Janssen Ad26.COV2.S vaccine among healthcare workers (HCWs) in South Africa. Here, we present the safety data. | en_US |
| dc.description.department | Paediatrics and Child Health | en_US |
| dc.description.department | School of Health Systems and Public Health (SHSPH) | en_US |
| dc.description.librarian | dm2022 | en_US |
| dc.description.sponsorship | Funding for the Sisonke Study was provided by: The National Department of Health through baseline funding to the South African Medical Research Council; the Solidarity Response Fund NPC; The Michael & Susan Dell Foundation; the ELMA Vaccines and Immunization Foundation; the ELMA Vaccines and Immunization Foundation; and the Bill & Melinda Gates Foundation. | en_US |
| dc.description.uri | https://journals.plos.org/plosmedicine | en_US |
| dc.identifier.citation | Takuva, S., Takalani, A., Seocharan, I., Yende-Zuma, N., Reddy, T., Engelbrecht, I. et al. (2022) Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial. PLoS Medicine 19(6): e1004024. https://doi.org/10.1371/journal.pmed.1004024. | en_US |
| dc.identifier.issn | 1549-1676 (online) | |
| dc.identifier.issn | 1549-1277 (print) | |
| dc.identifier.other | 10.1371/journal.pmed.1004024 | |
| dc.identifier.uri | https://repository.up.ac.za/handle/2263/88106 | |
| dc.language.iso | en | en_US |
| dc.publisher | Public Library Science | en_US |
| dc.rights | © 2022 Takuva et al. This is an open access article distributed under the terms of the Creative Commons Attribution License. | en_US |
| dc.subject | Safety | en_US |
| dc.subject | Effectiveness | en_US |
| dc.subject | Vaccines | en_US |
| dc.subject | Janssen Ad26.COV2.S vaccine | en_US |
| dc.subject | Healthcare workers (HCW) | en_US |
| dc.subject | South Africa (SA) | en_US |
| dc.title | Safety evaluation of the single-dose Ad26. COV2.S vaccine among healthcare workers in the Sisonke study in South Africa : a phase 3b implementation trial | en_US |
| dc.type | Article | en_US |
